{
    "clinical_study": {
        "@rank": "69003", 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the steady-state pharmacokinetics and\n      bioavailability of buprenorphine sublingual tablets vs. sublingual solution."
        }, 
        "brief_title": "Evaluation of Liquid vs. Tablet Buprenorphine - 6", 
        "completion_date": {
            "#text": "August 2000", 
            "@type": "Actual"
        }, 
        "condition": "Opioid-Related Disorders", 
        "condition_browse": {
            "mesh_term": "Opioid-Related Disorders"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        M/F ages 21-50. Meet DSM-IV criteria for opioid dependence. Agree to conditions of the\n        study and sign informed consent.\n\n        Exclusion Criteria:\n\n        Psychiatric disorder that requires medication therapy. History of seizures. Pregnant\n        and/or nuring women. Dependence on ETOH or benzodiazepines or other sedative/hypnotics.\n        Acute hepatitis. Other medical condtions that deem participation to be unsafe."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "50 Years", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": "1", 
        "firstreceived_date": "September 20, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00000341", 
            "org_study_id": "NIDA-3-0010-6", 
            "secondary_id": "Y01-3-0010-6"
        }, 
        "intervention": {
            "intervention_name": "Buprenorphine", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Buprenorphine"
        }, 
        "lastchanged_date": "August 26, 2008", 
        "location": {
            "facility": {
                "address": {
                    "city": "Los Angeles", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "90025"
                }, 
                "name": "Friends Research Institute"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Pharmacokinetics and Bioavailability of Liquid vs Tablet Buprenorphine", 
        "overall_official": {
            "affiliation": "Friends Research Institute, Inc.", 
            "last_name": "Walter Ling, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 2", 
        "primary_outcome": {
            "measure": "Subjective and observer rater physiological effects of bup"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00000341"
        }, 
        "source": "National Institute on Drug Abuse (NIDA)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Institute on Drug Abuse (NIDA)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "August 1996", 
        "study_design": "Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2008"
    }, 
    "geocoordinates": {
        "Friends Research Institute": "34.052 -118.244"
    }
}